Effects Of Ketocyclazocine Research Articles

Modulation of Histamine Release in the Rat Brain by K‐Opioid Receptors

The opioid modulation of histamine release was studied in rat brain slices labeled with L-[3H]histidine. The K(+)-induced [3H]histamine release from cortical slices was progressively inhibited by the preferential kappa-agonists ketocyclazocine, dynorphin A (1-13), Cambridge 20, spiradoline, U50,488H, and U69,593 in increasing concentrations. In contrast, the mu-agonists morphine, morphiceptin, and Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAGO) were ineffective as were the preferential delta-agonists [D-Ala2,D-Leu5]enkephalin (DA-DLE) and [D-Pen2,D-Pen5]enkephalin (DPDPE). Nor-binaltorphimine (nor-BNI) and MR 2266, two preferential kappa-antagonists, reversed the inhibitory effect of the various kappa-agonists more potently than did naloxone, with mean Ki values of 4 nM and 25 nM, respectively. The effects of ketocyclazocine and naloxone also were seen in slices of rat striatum, another brain region known to contain histaminergic nerve endings. We conclude that kappa-opioid receptors, presumably located on histaminergic axons, control histamine release in the brain. However, nor-BNI and naloxone failed, when added alone, to enhance significantly [3H]histamine release from cerebral cortex or striatum, and bestatin, an aminopeptidase inhibitor, failed to decrease K(+)-evoked [3H]histamine release. These two findings suggest that under basal conditions these kappa-opioid receptors are not tonically activated by endogenous dynorphin peptides. The inhibition of cerebral histamine release by kappa-agonists may mediate the sedative actions of these agents in vivo.

Effects of neonatal spinal cord serotonin depletion on opiate-induced analgesia in tests of thermal and mechanical pain

There is considerable evidence that serotonin (5-HT) is involved in the analgesic actions of various opiates. However, it is less clear which opioid receptor types interact with these descending systems and whether the various monoaminergic pathways are specific for different types of nociceptive signals. In the present study we lesioned the spinal cord serotonin pathways by neonatal spinal injections of 5,7-dihydroxytryptamine (5,7-DHT) and tested the analgesic effects of morphine and ketocyclazocine one and two weeks later using both mechanical and thermal noxious stimuli. The treatment depleted spinal cord serotonin by more than 90% while not affecting norepinephrine levels. The effects of morphine were greatly attenuated in the depleted animals when the thermal noxious stimulus was applied. The analgesic actions of morphine were only slightly affected when the mechanical stimulus was applied. The effects of ketocyclazocine were not reduced by the treatment. The results further buttress the conclusion that at least part of morphine's analgesic effects are mediated by descending serotonin systems and that these systems are primarily effective against a thermal stimulus. The data suggest that non-5HT brainstem system(s) are involved in morphine-induced analgesia to a mechanical noxious stimulus.

Opiates and medial hypothalamic knife cuts cause hyperphagia through different mechanisms.

Several experiments were performed to determine whether the hyperphagia caused by medial hypothalamic knife cuts and that induced by opiate agonists are mediated by a common mechanism. In the first set of experiments, male Sprague-Dawley rats were given bilateral parasagittal medial hypothalamic knife cuts or a sham procedure and fed a high-fat Crisco-chow diet. Knife-cut and sham-operated rats were approximately equally sensitive to the suppressive effects of naloxone on food intake. The kappa opiate receptor agonist ketocyclazocine generally increased daytime food intake in sham-operated rats; in contrast, the normal hyperphagia of knife-cut rats was in most cases either unchanged or decreased by ketocyclazocine. In a second set of experiments, neither diet composition nor hypothalamic knife cuts significantly affected the feeding responses to naloxone or the stimulatory effects of the kappa agonist butorphanol tartrate. It was hypothesized that the differential effects of ketocyclazocine in knife-cut and sham-operated rats are a consequence of the sedative effects of the drug combined with the elevated baseline of the knife-cut subjects. This hypothesis was supported by a third experiment, in which ketocyclazocine also reduced nocturnal intake in unoperated rats and butorphanol increased intake. That feeding responses to naloxone and butorphanol were essentially unchanged by hypothalamic knife cuts suggests that the opioid feeding system is independent of the longitudinal feeding inhibitory pathway believed to be involved in knife-cut-induced hyperphagia.

Effects of ketocyclazocine alone and in combination with naloxone on schedule-controlled responding in squirrel monkeys

A multiple, fixed interval 5 minutes, fixed ratio 30, schedule of food presentation (Mult FI FR) was used to evaluate the effects of ketocyclazocine, a kappa-receptor agonist, in four squirrel monkeys. Two monkeys were initially trained with 1-minute time-out (TO) periods between the components of the multiple schedule and two monkeys were initially trained without these TO periods. Ketocyclazocine dose-response functions were determined for each monkey under their original training conditions and then the conditions were reversed and dose-response functions were re-determined under the new conditions. Ketocyclazocine consistently decreased rates of responding during the FR component of the multiple schedule under both TO and no TO conditions. Under the FI component, ketocyclazocine's effects differed dependent upon dose, conditioning history, and the presence or absence of TO periods. Intermediate doses of ketocyclazocine (0.01-0.056 mg/kg) increased FI rates of responding under the no TO condition in monkeys originally trained under this condition; however, ketocyclazocine did not increase FI rates of responding under the no TO condition in monkeys originally trained under the TO condition. Under the TO condition, intermediate doses of ketocyclazocine did not increase FI rates of responding. High doses of ketocyclazocine (0.1 and 0.17 mg/kg) decreased FI rates of responding in all monkeys under both the TO and no TO conditions Naloxone, in doses up to those which decreased responding when given alone, failed to antagonize completely the rate decreasing effects of ketocyclazocine.